Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452775 · ClinicalTrials.gov registry record · Phase 1
Autologous OC-L Vaccine and Ovarian Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02452775 is a Phase 1 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 3 participants.
The verdict
NCT02452775, a Phase 1 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a randomized pilot trial to test the addition of 2 investigational agents, Montanide and poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine (OC-L) administered with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Interventions
- OTHER Montanide
- BIOLOGICAL OC-L
- OTHER poly-ICLC (Hiltonol),
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452775
The ClinicalTrials.gov registry entry for NCT02452775 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Montanide is the first listed.
NCT02452775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02452775 about?
NCT02452775 is a clinical study titled "Autologous OC-L Vaccine and Ovarian Cancer". This is a randomized pilot trial to test the addition of 2 investigational agents, Montanide and poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine (OC-L) administered with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal...
What is the current status of trial NCT02452775?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2015-05. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT02452775?
The interventions under investigation include: Montanide (OTHER), OC-L (BIOLOGICAL), poly-ICLC (Hiltonol), (OTHER).
Who is sponsoring clinical trial NCT02452775?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.